|
1
|
Wang Z, Song W, Aboukameel A, Mohammad M,
Wang G, Banerjee S, Kong D, Wang S, Sarkar FH and Mohammad RM:
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth
and invasion in pancreatic cancer. Int J Cancer. 123:958–966. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sheehan JK, Brazeau C, Kutay S, Pigeon H,
Kirkham S, Howard M and Thornton DJ: Physical characterization of
the MUC5AC mucin: a highly oligomeric glycoprotein whether isolated
from cell culture or in vivo from respiratory mucous secretions.
Biochem J. 347:37–44. 2000. View Article : Google Scholar
|
|
3
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ho JJL, Crawley S, Pan PL, Farrelly ER and
Kim YS: Secretion of MUC5AC mucin from pancreatic cancer cells in
response to forskolin and VIP. Biochem Biophys Res Commun.
294:680–686. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tecchio C, Huber V, Scapini P, Calzetti F,
Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G,
Rivoltini L and Cassatella MA: IFNalpha-stimulated neutrophils and
monocytes release a soluble form of TNF-related apoptosis-inducing
ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on
leukemic cells. Blood. 103:3837–3844. 2004. View Article : Google Scholar
|
|
6
|
Stockmeyer B, Beyer T, Neuhuber W, Repp R,
Kalden JR, Valerius T and Herrmann M: Polymorphonuclear
granulocytes induce antibody-dependent apoptosis in human breast
cancer cells. J Immunol. 171:5124–5129. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Challacombe JM, Suhrbier A, Parsons PG,
Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le
TT, Hoang-Le D and Ogbourne SM: Neutrophils are a key component of
the antitumor efficacy of topical chemotherapy with
ingenol-3-angelate. J Immunol. 177:8123–8132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koga Y, Matsuzaki A, Suminoe A, Hattori H
and Hara T: Neutrophil-derived TNF-related apoptosis-inducing
ligand (TRAIL): a novel mechanism of antitumor effect by
neutrophils. Cancer Res. 64:1037–1043. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kemp TJ, Ludwig AT, Earel JK, Moore JM,
Vanoosten RL, Moses B, Leidal K, Nauseef WM and Griffith TS:
Neutrophil stimulation with Mycobacterium bovis bacillus
Calmette-Guérin (BCG) results in the release of functional soluble
TRAIL/Apo-2L. Blood. 106:3474–3482. 2005.
|
|
10
|
de Vries EG, Gietema JA and de Jong S:
Tumor necrosis factor-related apoptosis-inducing ligand pathway and
its therapeutic implications. Clin Cancer Res. 12:2390–2393.
2006.
|
|
11
|
Voortman J and Resende TP: TRAIL therapy
in non-small cell lung cancer cells: sensitization to death
receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol
Cancer Ther. 6:2103–2112. 2007. View Article : Google Scholar
|
|
12
|
Hoshi H, Sawada T, Uchida M, Saito H,
Iijima H, Toda-Agetsuma M, Wada T, Yamazoe S, Tanaka H, Kimura K,
Kakehashi A, Wei M, Hirakawa K and Wanibuchi H: Tumor-associated
MUC5AC stimulates in vivo tumorigenicity of human pancreatic
cancer. Int J Oncol. 38:619–627. 2011.PubMed/NCBI
|
|
13
|
Hernandez-Ilizaliturri FJ, Jupudy V,
Ostberg J, Oflazoglu E, Huberman A, Repasky E and Czuczman MS:
Neutrophils contribute to the biological antitumor activity of
rituximab in a non-Hodgkin’s lymphoma severe combined
immunodeficiency mouse model. Clin Cancer Res. 9:5866–5873.
2003.PubMed/NCBI
|
|
14
|
Singh PK and Hollingsworth MA: Cell
surface-associated mucins in signal transduction. Trends Cell Biol.
16:467–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lane D, Côté M, Grondin R, Couture MC and
Piché A: Acquired resistance to TRAIL-induced apoptosis in human
ovarian cancer cells is conferred by increased turnover of mature
caspase-3. Mol Cancer Ther. 5:509–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lane D, Robert V, Grondin R, Rancourt C
and Piché A: Malignant ascites protect against TRAIL-induced
apoptosis by activating the PI3K/Akt pathway in human ovarian
carcinoma cells. Int J Cancer. 121:1227–1237. 2007. View Article : Google Scholar
|
|
17
|
Di Carlo E, Forni G, Lollini P, Colombo
MP, Modesti A and Musiani P: The intriguing role of
polymorphonuclear neutrophils in antitumor reactions. Blood.
97:339–345. 2001.PubMed/NCBI
|
|
18
|
Alvarez MJ, Prada F, Salvatierra E, Bravo
AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE and Podhajcer OL:
Secreted protein acidic and rich in cysteine produced by human
melanoma cells modulates polymorphonuclear leukocyte recruitment
and antitumor cytotoxic capacity. Cancer Res. 65:5123–5132. 2005.
View Article : Google Scholar
|
|
19
|
Chen YL, Chen SH, Wang JY and Yang BC: Fas
ligand on tumor cells mediates inactivation of neutrophils. J
Immunol. 171:1183–1191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sanford MA, Yan Y, Canfield SE, Hassan W,
Selleck WA, Atkinson G, Chen SH and Hall SJ: Independent
contributions of GR-1+ leukocytes and Fas/FasL interactions to
induce apoptosis following interleukin-12 gene therapy in a
metastatic model of prostate cancer. Hum Gene Ther. 12:1485–1498.
2001.PubMed/NCBI
|
|
21
|
Niitsu N, Khori M, Hayama M, Kajiwara K,
Higashihara M and Tamaru J: Phase I/II study of the rituximab-EPOCT
regimen in combination with granulocyte colony-stimulating factor
in patients with relapsed or refractory follicular lymphoma
including evaluation of its cardiotoxicity using B-type natriuretic
peptide and troponin T levels. Clin Cancer Res. 11:697–702.
2005.
|
|
22
|
Otten MA, Rudolph E, Dechant M, Tuk CW,
Reijmers RM, Beelen RH, van de Winkel JG and van Egmond M: Immature
neutrophils mediate tumor cell killing via IgA but not IgG Fc
receptors. J Immunol. 174:5472–5480. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA
and Goodwin RG: Identification and characterization of a new member
of the TNF family that induces apoptosis. Immunity. 3:673–682.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schimmer AD: Inhibition of apoptosis
proteins: translating basic knowledge into clinical practice.
Cancer Res. 64:7183–7190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei Y, Fan T and Yu M: Inhibitor of
apoptosis proteins and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 40:278–288. 2009. View Article : Google Scholar
|
|
26
|
Komatsu M, Jepson S, Arango ME, Carraway
CAC and Carraway KL: Muc4/sialomucin complex, an intramembrane
modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and
suppresses apoptosis in a xenotransplanted tumor. Oncogene.
20:461–470. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Workman HC, Sweeney C and Carraway KL III:
The membrane mucin Muc4 inhibits apoptosis induced by multiple
insults via ErbB2-dependent and ErbB2-independent mechanisms.
Cancer Res. 69:2845–2852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baratelli F, Krysan K, Heuzé-Vourc’h N,
Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M and Dubinett
SM: PGE2 confers survivin-dependent apoptosis resistance in human
monocyte-derived dendritic cells. J Leukoc Biol. 78:555–564. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leone V, di Palma A, Ricchi P, Acquaviva
F, Giannouli M, Di Prisco AM, Iuliano F and Acquaviva AM: PGE2
inhibits apoptosis in human adenocarcinoma Caco-2 cell line through
Ras-PI3K association and cAMP-dependent kinase A activation. Am J
Physiol Gastrointest Liver Physiol. 293:G673–G681. 2007. View Article : Google Scholar : PubMed/NCBI
|
